logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The pharmaceutical industry once again sets a record for investment in R&D in Spain

Source: www.lavozdegalicia.es

The sector has registered an investment in research and development of 1,211 million euros in 2019, 5.2% more than the previous year
In these months of health crisis, pharmaceutical companies are being essential to maintain the supply of medicines, as well as to investigate treatments and vaccines that are effective against covid-19. For this sector, investments destined to R&D activities are really important, even more so at a time as critical as this. “This situation has highlighted the value of research,” says Javier Urzay, general deputy director of Farmaindustria.

 

In this sense, the figures seem to indicate that we are on the right track since, during the last year, Spain allocated a total of 1,211 million euros in R&D, which represents a historical record for the pharmaceutical sector. Thus, the increase in investment during 2019 was 5.2% compared to the previous year, according to the latest Survey on R&D Activities carried out by Farmaindustria among its associates.

“Almost 20% of all industrial R&D carried out in our country is carried out by the pharmaceutical industry. One out of every five euros invested in research in Spain comes from our sector. And this represents almost 8% of all R&D, taking into account public and private research, ”recalls Javier Urzay.

“In Spain, one out of every five euros invested in research comes from the pharmaceutical sector”
The document also highlights that in the last decade, research projects developed in collaboration with hospitals and public and private centers have grown 3.6 percentage points. This expense represents 43.6% of the total investment of pharmaceutical companies and translates to 528 million euros in 2019, while the investment made in the research centers of the companies themselves exceeded 683 million euros.

 

At the geographical level, all the autonomous communities captured extramural investments by the innovative pharmaceutical industry, with special relevance from Madrid and Catalonia, which accounted for 28% and 25.7% -respectively- of the total investment. In the case of Galicia, this investment was 19.91 million euros. “This important contribution from the industry in health centers not only contributes to their financing but also, and very especially, to the participation of Spanish scientists and health professionals in the scientific avant-garde”, say from Farmaindustria.

Also, with regard to the breakdown of investment in R&D by research phases, the document highlights that almost 60% is concentrated in the clinical phase, where Spain plays a prominent international role.

The report also shows positive data regarding an increasingly qualified job. The direct employment of the companies associated with Farmaindustria in research and development tasks increased by 4.2% in 2019 and reached 5,006 people, which represents a new all-time high. To this data is added the high qualification of the research staff of the pharmaceutical industry, since almost 88% of researchers are university graduates. «This high preparation of our professionals is a differentiating element with respect to the rest of the sectors. A quality job is synonymous with wealth for the countries. And if we add that employment in pharmaceutical companies is, for the most part, indefinite and equal, we have the ideal equation to consider the pharmaceutical industry as a lever for recovery in Spain ”, points out Javier Urzay. “A quality job is synonymous with wealth for the countries” A key sector for the country’s economic recovery The pandemic has highlighted the close relationship between the economy and health and how this sector in general, and the pharmaceutical sector in In particular, they have become strategic for the economic recovery facing Spain. Here, experts agree that health spending should be a policy priority in the coming years. “It is an investment, not a mere expense that we can do without due to budgetary problems,” said Antón Costas, Professor of Economic Policy at the University of Barcelona, ??during a digital meeting organized by Farmaindustria last month. For Costas, investment in health is a safe bet and he believes that only in this way would Spain get closer to European figures. «Since the 1980s, the drop in health spending has been related to the decline in the economic fabric. Other leading countries, such as Germany, France or the United States, have a system that enhances health research, therefore promoting the strength of their economic structures. “Health spending is an investment, not a mere expense that we can do without in the face of budgetary problems” Analysts also affirm that biomedical research – due to its impact on health – is going to become one of the axes that go to define the immediate future of society. And the good news, as stated by Farmaindustria, is that Spain is in a privileged position in this field. “Our country is already a benchmark in conducting clinical trials and for some large pharmaceutical companies it is the second country in trials after the United States.” In the end, if this pandemic has served us anything, it is to become aware of how much we depend on science and research. “Now we know with much more certainty that there is no economy without health, there is no health without drugs and there are no drugs without research,” explains the CEO of Farmaindustria, Humberto Arnés. “That there is a sector so committed to innovation is the best guarantee for the future of our country and part of the solution to the deep health, economic and social crisis that we are going through.”

 

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.